Microenvironment-Dependent Gradient of CTL Exhaustion in the AE17sOVA Murine Mesothelioma Tumor Model
暂无分享,去创建一个
J. Aerts | L. Bradley | P. Katsikis | D. Nelson | Y. Mueller | M. van Meurs | J. Hope | I. Brouwers-Haspels | Christopher J Stairiker | C. Kiernan | P. I. Spantidea | L. Rijsbergen | Christopher J. Stairiker | P. Spantidea | Caoimhe H Kiernan | Inge Brouwers-Haspels
[1] E. Wherry,et al. CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. , 2019, Annual review of immunology.
[2] J. Allison,et al. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.
[3] O. Lantz,et al. Induction of anergic or regulatory tumor-specific CD4+ T cells in the tumor-draining lymph node , 2018, Nature Communications.
[4] T. Schumacher,et al. T Cell Dysfunction in Cancer. , 2018, Cancer cell.
[5] A. Ribas,et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) , 2017, The Lancet.
[6] Chiun-Sheng Huang,et al. TGF‐β1 secreted by Tregs in lymph nodes promotes breast cancer malignancy via up‐regulation of IL‐17RB , 2017, EMBO molecular medicine.
[7] D. Schadendorf,et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.
[8] Tithi Ghosh,et al. Tumor promoting role of anti-tumor macrophages in tumor microenvironment. , 2017, Cellular immunology.
[9] B. Stanger,et al. Lack of immunoediting in murine pancreatic cancer reversed with neoantigen. , 2016, JCI insight.
[10] M. Delorenzi,et al. High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival , 2016, The Journal of experimental medicine.
[11] E. Elkord,et al. Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting , 2016, Vaccines.
[12] D. Nelson,et al. Murine mesothelioma induces locally-proliferating IL-10+TNF-α+CD206−CX3CR1+ M3 macrophages that can be selectively depleted by chemotherapy or immunotherapy , 2016, Oncoimmunology.
[13] J. Ahn,et al. Pembrolizumab for the treatment of non-small cell lung cancer , 2016, Expert opinion on biological therapy.
[14] A. Madi,et al. TIM3 Mediates T Cell Exhaustion during Mycobacterium tuberculosis Infection , 2016, PLoS pathogens.
[15] A. Arina,et al. Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment. , 2016, Seminars in immunology.
[16] E. Buchbinder,et al. CTLA-4 and PD-1 Pathways , 2016, American journal of clinical oncology.
[17] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[18] E. Wherry,et al. Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.
[19] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[20] C. Mamotte,et al. Mesothelioma Tumor Cells Modulate Dendritic Cell Lipid Content, Phenotype and Function , 2015, PloS one.
[21] John J. Erickson,et al. Programmed Death-1 Impairs Secondary Effector Lung CD8+ T Cells during Respiratory Virus Reinfection , 2014, The Journal of Immunology.
[22] M. King,et al. Microenvironment of Tumor-Draining Lymph Nodes: Opportunities for Liposome-Based Targeted Therapy , 2014, International journal of molecular sciences.
[23] A. Farina,et al. CD160-Associated CD8 T-Cell Functional Impairment Is Independent of PD-1 Expression , 2014, PLoS pathogens.
[24] O. Lund,et al. T-bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection , 2014, PLoS pathogens.
[25] Xuetao Cao,et al. Human hepatocellular carcinoma-infiltrating CD4+CD69+Foxp3− regulatory T cell suppresses T cell response via membrane-bound TGF-β1 , 2014, Journal of Molecular Medicine.
[26] Mark G. Lewis,et al. Type I Interferon Upregulates Bak and Contributes to T Cell Loss during Human Immunodeficiency Virus (HIV) Infection , 2013, PLoS pathogens.
[27] T. Padera,et al. Lymphatic function and immune regulation in health and disease. , 2013, Lymphatic research and biology.
[28] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[29] C. Thompson,et al. At the Bench: Preclinical rationale for CTLA‐4 and PD‐1 blockade as cancer immunotherapy , 2013, Journal of leukocyte biology.
[30] G. Freeman,et al. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. , 2013, Cancer research.
[31] Burton E. Barnett,et al. Progenitor and Terminal Subsets of CD8+ T Cells Cooperate to Contain Chronic Viral Infection , 2012, Science.
[32] A. Oxenius,et al. Antigen amount dictates CD8+ T‐cell exhaustion during chronic viral infection irrespective of the type of antigen presenting cell , 2012, European journal of immunology.
[33] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[34] E John Wherry,et al. T cell exhaustion , 2011 .
[35] D. Dolfi,et al. Dendritic Cells and CD28 Costimulation Are Required To Sustain Virus-Specific CD8+ T Cell Responses during the Effector Phase In Vivo , 2011, The Journal of Immunology.
[36] Mario Roederer,et al. SPICE: Exploration and analysis of post‐cytometric complex multivariate datasets , 2011, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[37] J. Mulligan,et al. Tumors induce the formation of suppressor endothelial cells in vivo , 2010, Cancer Immunology, Immunotherapy.
[38] P. Katsikis,et al. Chronic Antigen Stimulation Alone Is Sufficient to Drive CD8+ T Cell Exhaustion1 , 2009, The Journal of Immunology.
[39] S. Cornwall,et al. Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells , 2009, European Respiratory Journal.
[40] R. Zheng,et al. Tumor-Induced CD11b+Gr-1+ Myeloid Cells Suppress T Cell Sensitization in Tumor-Draining Lymph Nodes1 , 2008, The Journal of Immunology.
[41] D. Vignali,et al. How regulatory T cells work , 2008, Nature Reviews Immunology.
[42] D. Sojka,et al. Mechanisms of regulatory T‐cell suppression – a diverse arsenal for a moving target , 2008, Immunology.
[43] G. Rabinovich,et al. Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.
[44] S. Szabo,et al. Antigen-driven effector CD8 T cell function regulated by T-bet , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[45] B. Robinson,et al. IL-2 Intratumoral Immunotherapy Enhances CD8+ T Cells That Mediate Destruction of Tumor Cells and Tumor-Associated Vasculature: A Novel Mechanism for IL-2 1 , 2003, The Journal of Immunology.
[46] Hao Shen,et al. Control of Effector CD8+ T Cell Function by the Transcription Factor Eomesodermin , 2003, Science.
[47] J. Altman,et al. Increased CD95/Fas-induced apoptosis of HIV-specific CD8(+) T cells. , 2001, Immunity.
[48] Saroja Ramanujan,et al. Differential Dynamics of CD4+ and CD8+ T-Lymphocyte Proliferation and Activation in Acute Simian Immunodeficiency Virus Infection , 2000, Journal of Virology.
[49] J. Allison,et al. Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.
[50] Kristin A. Hogquist,et al. T cell receptor antagonist peptides induce positive selection , 1994, Cell.
[51] D. Wiley,et al. HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[52] E. Buchbinder,et al. CTLA-4 and PD-1 Pathways , 2016, American Journal of Clinical Oncology.
[53] Taeg S. Kim,et al. The effector T cell response to influenza infection. , 2015, Current topics in microbiology and immunology.
[54] A. Liston,et al. Regulatory T Cells , 2011, Methods in Molecular Biology.